Antheia key facts
as of Oct 2026- Operator of a biotechnology company intended to develop plant-inspired medicines.
- Antheia is valued at approximately $240.0M as of Oct 2026 (last reported valuation).
- It has raised $176.2M across 5 recorded rounds; the latest was Later Stage VC (Series C) ($80.0M) in Jan 2026.
- Notable investors include US National Science Foundation, Viking Global Investors, National Institutes of Health, In-Q-Tel, Western Technology Investment — 23 tracked in total.
- Antheia has filed 3 Form Ds with the SEC since 2015, most recently Sep 2018 ($9.2M sold to 5 investors).
- Status: Privately Held (backing).
Antheia's last reported valuation, Jun 2021. Nothing priced has surfaced since.
- ·The complete investor list: 23 names
- ·Watch Antheia: the Monday email on marks, rounds and moves
Antheia funding rounds
5 roundsWho backs Antheia
23+Antheia valuation
Antheia's last reported valuation was $240 million in Jun 2021. No priced round, secondary trade or fund mark has surfaced since.
How much has Antheia raised?
Antheia has raised $176 million across 5 recorded rounds since 2015. The largest was a $9.2 million early-stage round in Aug 2018; the most recent was an $80 million Series C in Jan 2026.
Antheia has filed 3 Form Ds with the SEC since 2015, most recently in Sep 2018 ($9.2 million sold to 5 investors).
Antheia investors
23 investors are on record for Antheia, including US National Science Foundation, Viking Global Investors, National Institutes of Health and In-Q-Tel. By type, the record holds 6 venture capital firms and 2 family offices. The Series C in Jan 2026 drew 10 investors.
Comparable companies
Comparable biotechnology names by valuation on PrivateMarketView: Ansa Biotechnologies ($269 million), Ambros Therapeutics ($250 million) and Gameto ($243 million).
About Antheia
Operator of a biotechnology company intended to develop plant-inspired medicines. The company's cost-competitive, plant-based medicines are made using synthetic biology, informatics, and fermentation technology to harness beneficial molecules from plants to create active pharmaceutical ingredients, enabling healthcare organizations to provide patients with natural and healthier medication.
- Industry
- Biotechnology
- Sector
- Healthcare
- HQ
- Menlo Park, CA, United States
- Founded
- 2013
- Employees
- 65
- Website
- antheia.bio/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.